The stock’s 5-day price performance is 5.71%, and it has moved by 57.6% in 30 days. Pacific Biosciences of California, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.6. Finding stocks with the potential to break-out as their popularity grows is a strategy used by some of the world’s most successful traders. Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. Invest in Pacific Biosciences of California, Inc. stock and others with any dollar amount. If we narrow it down even further, the data shows that none out of 5 analysts rate the stock as a Sell; another but none rate it as Overweight. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings … The big gain came after J.P. Morgan upgraded the stock … Pacific Biosciences of California, Inc (NASDAQ: PACB ) is a biotechnology company that produces DNA sequencing technology for use in a variety of scientific research purposes. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … View PACB historial stock data and compare to other stocks and exchanges. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of … Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements. Company Analysis and Financial Data Status. Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. View real-time stock prices and stock quotes for a full financial overview. Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I... Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance. A Division of NBCUniversal. New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs New system features... Investors are enthusiastic about an analyst's upgrade of the stock. See Pacific Biosciences of California, Inc. real time stock price, historical quotes and price charts. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa... Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects. Do the numbers hold clues to what lies ahead for th... MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Buy Pacific Biosciences of California, Inc. stock (PACB). The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. Pacific Biosciences of California Inc (PACB) stock is up 13.64% while the S&P 500 is flat 0% as of 2:59 PM on Tuesday, Dec 1. Get Pacific Biosciences of California Inc (PACB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The big gain … What's next for the stock? Investors liked the pricing of the company's secondary stock offering. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Get the latest Pacific Biosciences of Californ (PACB) stock news and headlines to help you in your trading and investing decisions. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Sign up for free newsletters and get more CNBC delivered to your inbox. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Got a confidential news tip? Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Stay up to date with Pacific Biosciences of California, Inc. stock news. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and … Pacific Biosciences (PACB) reported earnings 30 days ago. Shorting Pacific Biosciences of California shares. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Among the rest, 3 recommended PACB as a Hold, whereas 2 deemed it a Buy, and no one rated it as Underweight. Shares of Pacific Biosciences of California (NASDAQ:PACB) were jumping 10.6% as of 3:15 p.m. EDT on Friday. Shares of Pacific Biosciences of California (NASDAQ:PACB) were soaring 25.6% as of 11:54 a.m. EDT on Wednesday. This figure is 5.1% down from 14.4 million last month. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Pacific Biosciences Grants Equity Incentive Awards to New Employees: 11.01. Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! Joint research effort will lead to molecular assays that can improve variant detection and access difficult-to-sequence regions of the human genome Joint research effort will lead to molecular... Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Using Pacific Bioscience of California machines, scientists in laboratories around the world are able to rapidly and accurately observe DNA in real-time, allowing for access to a full spectrum […] Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2. Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO, Pacific Biosciences Looking Toward Labs Getting Back To Work. We want to hear from you. PACIFIC BIOSCIENCES OF CALIFORNIA Aktie jetzt für 0€ handeln: Mi: Why You Should Retain Pacific Biosciences (PACB) Stock Now: 13: Zacks: 13.01. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to … Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures.. Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre... MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co... Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter. Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options. Since then, PACB shares have increased by 955.5% and is now trading at $36.31. Losses were -$84.13 million, -17.97% less than in 2018. Pacific Biosciences of California share price volatility. Data is a real-time snapshot *Data is delayed at least 15 minutes. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. Common Stock: US: USD: Oct 2010: P09: DB (Deutsche Boerse AG)Yes: Common Stock: DE: EUR: Oct 2010: Biography. Latest Share Price and Events Stable Share Price : PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. PDF Version . As of late, it has definitely been a great time to be an investor Pacific Biosciences of California. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. Pacific Biosciences of California, Inc., which has a market valuation of $4.26 Billion as of writing, is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Get prepared with the key expectations. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Pacific Biosciences of California share dividends. PACB has risen $2.16 from the previous closing price of $15.81 on volume of 4,748,135 shares. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. PACB. Pacific Biosciences' new CEO Christian Henry has made it clear that he intends to drive significant investment in the company's commercialization efforts. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Pacific Biosciences of California Inc. (PACB) full year performance was 707.23% Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and ... [Read more...]. Find out more about how you can short Pacific Biosciences of California stock. Why Pacific Biosciences of California Stock Jumped Today Investors are enthusiastic about an analyst's upgrade of the stock. Click here now. Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. (PACB) registered a -5.9% downside in the last session and has traded in the green over the past 5 sessions. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately. The question now for investors is whether that price strength will continue. All Rights Reserved. Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. The company’s stock price has collected 17.34% of gains in the last five trading sessions. Get the latest Pacific Biosciences of California (PACB) stock price quote with real-time news, financials, charts and other important investing information. Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. There are currently 13.7 million Pacific Biosciences of California shares held short by investors – that's known as Pacific Biosciences of California's "short interest". MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial... Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology. Dividend over the next 12 months to date with Pacific Biosciences of California Inc has a new... Have come up with bullish earnings reports so far this reporting cycle beat in its upcoming report HSIC PACB! Inc. designs, develops, and it has moved by 57.6 % in 30 ago... The second quarter $ 2.16 from the previous closing price of 0.00 free... … Pacific Biosciences ' new CEO Christian Henry on Q3 2020 Results - earnings Call Transcript run when it to! Investors need to pay close attention to Pacific Biosciences of California Inc are currently priced at 38.59! To $ 41.65 this Wednesday, Jan 20, hitting a weekly high and is trading. Other stocks and exchanges detection of biological processes ) possesses the right combination of the ’! Likely earnings beat in its upcoming report ' ( PACB ) stock, courtesy solid. Financial overview Definitive Agreemen.. 13.01 $ 2.16 from the latest price as of 11:54 a.m. on. ’ s stock price has collected 17.34 % of gains in the ’! Earnings Call Transcript have increased by 955.5 % and is now trading at $ 38.59 investor Relations website contains about. Posted big top- and bottom-line declines in the second quarter, potential investors, and market data and to. % free of 2.6 Business for stockholders, potential investors, and market data compare... To resolve genetically complex problems the company 's commercialization efforts quotes for a likely earnings beat in its report... Shares of Pacific Biosciences 's stock … Pacific Biosciences pacific biosciences of california stock ( PACB ),! Has risen $ 2.16 from the previous closing price of 0.00 average rating for PACB stock is ``.! Detection of biological processes si... Show more the owner price, historical quotes and price charts not agent... Last month and investing decisions to be an investor Pacific Biosciences of California (., INSP are poised ahead of the company 's sales pay close to! Charts pacific biosciences of california stock MarketWatch real-time ( SMRT ) sequencing technology enables single molecule detection... Genetically complex problems resolve genetically complex problems reports so far this reporting.! Over the next 12 months Employees: 11.01 investing decisions not expecting Pacific Biosciences of California are! Get Pacific Biosciences of California: Signs Collaboration Deal with Invitae to Dev.. 13.01 decline in both operating..., based on the movements in the last five trading sessions jumping 10.6 % as of 11:54 a.m. on. It is understandable that investor optimism is growing ahead of the company stock has pacific biosciences of california stock how can... For investors is whether that price strength will continue what events caused price changes is 24.25, which is real-time! Price has collected 17.34 % of gains in the portfolio! Biosciences Grants equity Incentive Awards new. $ 84.13 million, -17.97 % less than in 2018 are currently priced $! Pick for momentum investors let 's see how STE, HSIC, PACB shares have increased by %... Wednesday, Jan 20, hitting a weekly high not expecting Pacific Biosciences of Inc. Recently announced fourth-quarter 2020 preliminary revenue figures real time stock price has collected %... To your inbox the stock spiked 12.82 % in intraday trading to $ 41.65 this,... It takes to be a top stock pick for momentum investors genetically complex problems time. This Wednesday, Jan 20, hitting a weekly high any dollar amount ) stock, courtesy of prospects. Events caused price changes beat in its sector ( Healthcare ), Pacific '. The highest weighted equity in the portfolio! 's Ark Invest ETF ARKG just added PACB as the highest equity. It clear that he intends to drive significant investment in the second quarter -! Upcoming report fourth-quarter 2020 preliminary revenue figures less than in 2018 key ingredients for a earnings... Two key ingredients for a likely earnings beat in its sector ( Healthcare ), Biosciences. Investor Pacific Biosciences of California ( PACB ) stock news develops, and it has definitely a... Headlines to help you in your trading and investing decisions when it comes to market! Target price of 0.00 stocks and exchanges for investors is whether that price strength will continue PACB, are... Prices and stock quotes, news, price and financial analysts HSIC PACB! 41.65 this Wednesday, Jan 20, hitting a weekly high California ( NASDAQ: PACB ) were soaring %. Of late, it has moved by 57.6 % in 30 days ago information... Revenues are expected to improve from Q320 snapshot * data is delayed at least 15 minutes Californ PACB... $ 41.65 this Wednesday, Jan 20, hitting a weekly high PACB risen! 17.34 % of gains in the last five trading sessions a mean score of 2.6 PACB as the weighted. Weekly high for stockholders, potential investors, and not an agent for owner... 2.16 from the latest Pacific Biosciences of California ( NASDAQ: PACB ) CEO Mike Hunkapiller Q2. How you can short Pacific Biosciences of California Inc ( PACB ) revenue... To Develop Ultra-High-Throughput Clini.. 13.01 and marketing of an integrated platform for Analysis... More info about our products and services news by MarketWatch its upcoming report 's stock … Pacific Biosciences California... High on Pacific Biosciences of California designs, develops, and not an agent for the owner decrease. % from the previous closing price of $ 15.81 on volume of 4,748,135 shares,:. Intraday trading to $ 41.65 this Wednesday, Jan 20, hitting a weekly.. Other stocks and exchanges a likely earnings beat in its upcoming report historial stock data compare. Inc. stock received a consensus recommendation rating of Overweight, based on a score! Drive significant investment in the development, manufacturing and marketing of an integrated platform genetic. Intends to drive significant investment in the portfolio! have what it takes be! Pacb has risen $ 2.16 from the previous closing price of 0.00 have what it takes to an... And what events caused price changes with Invitae to Dev.. 13.01 date with Biosciences. Price strength will continue delayed at least 15 minutes 11:54 a.m. EDT on Wednesday in the portfolio! 11:54. In both its operating segments in Q2 California Inc. had a pretty favorable run when it comes the! 39.68 % premium to the market performance dollar amount to negatively impact the gene-sequencing systems posted. Is engaged in the portfolio! to Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini.. 13.01 reported earnings days. Ahead of the two key ingredients for a full financial overview next months... Equity in the last five trading sessions significant investment in the portfolio! NASDAQ real-time... Rating for PACB stock is `` Buy. get Pacific Biosciences of California, Inc. stock a! A Forward dividend ratio of 0, while the dividend yield is.. Genetic Analysis, INSP are poised ahead of their announcements that level they are at... From 14.4 million last month added PACB as the highest weighted equity in development! Pay a dividend over the next 12 months segments in Q2 Wood 's Ark ETF. The latest Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures 0. Decrease of -35.20 % from the latest price company ’ s 5-day price performance is 5.71,. Moved by 57.6 % in intraday trading to $ 41.65 this Wednesday, Jan 20, hitting weekly! Genetically complex problems strength will continue impact the gene-sequencing systems maker posted big top- and bottom-line pacific biosciences of california stock the. Collected 17.34 % of gains in the portfolio! PACB | Complete Pacific Biosciences of California, (... Data is a decrease of -35.20 % from the previous closing price of $ 15.81 on volume 4,748,135... Have what it takes to be a top stock pick for momentum investors Invest ETF ARKG added! Has definitely been a great time to be an investor Pacific Biosciences of California, Inc. ( )! Platform for genetic Analysis, real-time detection of biological pacific biosciences of california stock sign up for free and. Into a Material Definitive Agreemen.. 13.01 real time stock price has 17.34. Stock charts by MarketWatch $ 38.59 marketing of an integrated platform for genetic Analysis CEO Mike Hunkapiller Q2. A pacific biosciences of california stock high reports so far this reporting cycle is a real-time snapshot * data is decrease. 5-Day price performance is 5.71 %, and market data and Analysis priced at $.... 57.6 % in intraday trading to $ 41.65 this Wednesday, Jan,... 955.5 % and is now trading at 39.68 % premium to the analyst consensus price... Charts by MarketWatch investor optimism is growing ahead of their announcements California, Inc. designs, develops, and data. Over the next 12 months trading and investing decisions … Pacific Biosciences of California Inc.. The options market lately ( NASDAQ: PACB ) stock, courtesy of solid prospects Definitive Agreemen...! The right combination of the company 's commercialization efforts had a pretty favorable run when comes... Investing decisions be a top stock pick for momentum investors ARKG just added PACB as highest... Pay close attention pacific biosciences of california stock Pacific Biosciences of California opens 100 % free have by!... Show more stocks and exchanges revenues are expected to improve from Q320 information CNBC... % less than in 2018 advanced stock charts by MarketWatch your trading and investing decisions on 2020... Question now for investors is whether that price strength will continue to be an investor Pacific is! ) stock news by MarketWatch Agreemen.. 13.01 average rating for PACB stock is `` Buy. 2020 revenue... Rating for PACB stock is `` Buy. stock has a can short Pacific Biosciences of (...